Source：The Insides Company Limited
On：9th September 2024
Organisation：The Insides Company Limited
The Insides Company is proud to announce that The Insides® Neo, has been successfully added to the Singapore Medical Device Register (SMDR), marking a significant step forward in expanding the availability of life-saving treatment options for neonatal and pediatric patients in Southeast Asia.
The Insides Neo, a Class B medical device, is the world’s first chyme reinfusion device specifically designed for pediatric and neonatal patients suffering from severe intestinal failure. The device addresses a critical gap in the nutritional management of conditions such as necrotizing enterocolitis, a life-threatening illness with mortality rates of up to 50%, making it a leading cause of death in preterm infants.
Currently, the management of intestinal failure in neonatal and pediatric patients often involves the creation of a double enterostomy, which can lead to high-output stoma losses, causing dehydration and malnutrition. These patients are typically treated in neonatal intensive care units, where they may rely on invasive and costly parenteral or enteral nutrition, which may not always be feasible due to the compromised ability of their gut to absorb nutrients.
The Insides Neo offers an alternative method for managing these critically ill patients by providing essential nutritional and fluid support while reducing the risk of surgical and ostomy-related complications. Additionally, it streamlines clinical workflows for healthcare professionals by automating the chyme reinfusion process.
This Insides Neo will be distributed in Singapore by Bluestone Corporation Pte Ltd, marking a key milestone in its availability across Southeast Asia.
"We are thrilled to bring our novel chyme reinfusion therapy to the global market,” said Rob Davidson, Co-Founder and Chief Technology Officer at The Insides Company. “This milestone is particularly significant as it represents the first registration of The Insides Neo in the Southeast Asian market. We are eager to collaborate with our Singaporean partners at Bluestone Corporation to provide this critical treatment option for infants who need essential nutrients to grow and thrive."
About The Insides Company
The Insides Company Limited is a leading provider of automated chyme reinfusion solutions for the therapeutic treatment of intestinal failure that has resulted from either a high-output enterocutaneous fistula or enterostomy.
Contacts
Bluestone Corporation Pte Ltd
David Loh, General Manager
Phone：(65) 6767 1311
Email：enquiry@bluestone-corp.com
The Insides® Company Limited
Garth Sutherland, CEO
Phone：+64 9 887 9309
Email：sales@theinside.co
.png){kind=small}
